Session Time: 1:45pm-3:15pm
Location: Exhibit Hall C
Objective: Summarize change in QoL and health status by comparing scores from the EuroQuol-five domain questionnaire, five level response version (EQ-5D-5L) summary index and Visual Analog Scale (EQ-VAS) obtained at baseline for DBS naive PD patients to those scores obtained at 6 &/or 12-month post-DBS.
Background: EQ-5D index and EQ-VAS are popular standardized, generic (disease non-specific) self reporting instruments developed by an international group of multidisciplinary researchers (EuroQol) to evaluate the impact of treatment on health related QoL. When compared to disease specific instruments (e.g. PDQ-39 and SF-36), the EQ-5D-3L was a valid instrument to measure QoL in PD1. Our study may be the first to evaluate the effectiveness of DBS therapy for PD as measured by the EQ-5D-5L summary index and EQ-VAS.
Methods: The Product Surveillance Registry (PSR) is a prospective, long-term, multi-center global registry originated for DBS in 2009. EQ-5D-5L questionnaire, added in 2013, represents data from 632 patients collected at 25 centers who were implanted with a DBS device for PD from 2013-2016. Five domains of the EQ-5D-5L include mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Five tiered rating for each domain completed by each patient pre-operatively, and subsequent follow up visits at 6 month intervals. EQ-5D-5L summary index is scored -1.0 (worst)-1.0 (best) scale. EQ-VAS, a self-scoring vertical scale numbered 0 (worst) -100 (best) with patient scoring how good or bad their health is on the visit day.
Results: Subject demographics total N=632, (therapy naïve N=339, replacement device N= 292, not reported N=1) [table1]. EQ-5D-5L responses by visit for 164 matched pairs are shown in [table2]. EQ-5D-5L summary index scores compared 6 month (N=142) improved 0.14 (28%; p<. 0001), 12 month (N=103) improved 0.082 (15%; p=0.0314), either 6 or 12-month (improved 0.14 or 27% (p<. 0001). EQ-5D summary index scores sustained improvement over time [table 3]. VAS scores improved average 15 over baseline, 29% (p<. 0001) and showed improvement over time [table4].
Conclusions: Preliminary results from the PSR demonstrated significant improvement with EQ-5D-5L summary index score of 0.14 and together with the VAS scores a sustained improvement in health related QoL over time after DBS implant therapy for PD.
References: 1. Schrag A,Selai C, Jahanshahi M, Quinn NP The EQ-5D — a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson’s disease. JNNP 2000;69:67-73.
To cite this abstract in AMA style:M. Schiess, J. Krauss, J.-P. Azulay, E. Cuny, A. Lopez Rios, F. Farrokhi, S. Blond, T. Witt, C. Raftopoulos, J. Vesper, B. Van Dorn, T. Weaver, P. Konrad, S. Falowski, S. Palfi. Health related QoL as measured by the EQ-5D-5L in PD patients after DBS therapy: Preliminary results from the Product Surveillance Registry [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/health-related-qol-as-measured-by-the-eq-5d-5l-in-pd-patients-after-dbs-therapy-preliminary-results-from-the-product-surveillance-registry/. Accessed December 10, 2023.
« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/health-related-qol-as-measured-by-the-eq-5d-5l-in-pd-patients-after-dbs-therapy-preliminary-results-from-the-product-surveillance-registry/